News headlines about Accuray (NASDAQ:ARAY) have been trending somewhat positive on Thursday, according to Accern Sentiment. Accern rates the sentiment of news coverage by monitoring more than 20 million blog and news sources in real-time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Accuray earned a media sentiment score of 0.10 on Accern’s scale. Accern also gave news coverage about the medical equipment provider an impact score of 46.5406589419841 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.
Here are some of the media stories that may have impacted Accern’s analysis:
- Global Acoustic Neurinoma Treatment Market 2018 – Accuray, Huiheng Medical, Elekta, Varian Medical Systems (theanalystfinancial.com)
- Analysts’ Recommendations to Consider – Accuray Incorporated (NASDAQ: ARAY) (stockspen.com)
- Snapshot of Recent Traded Stock Accuray Incorporated (ARAY) -0.86% off from 200- SMA (nasdaqchronicle.com)
- Accuray Incorporated (ARAY) projected to achieve earnings growth of -13.20% for this year (wallstreetinvestorplace.com)
- Stock’s Technical Levels under Review – Accuray Incorporated (NASDAQ: ARAY) (stockspen.com)
Accuray stock traded up $0.15 during trading hours on Thursday, hitting $4.85. 314,201 shares of the stock traded hands, compared to its average volume of 928,577. The company has a debt-to-equity ratio of 2.66, a quick ratio of 0.99 and a current ratio of 1.54. The company has a market cap of $392.35, a PE ratio of -13.47 and a beta of 1.73. Accuray has a 1 year low of $3.60 and a 1 year high of $6.15.
ARAY has been the topic of several recent analyst reports. BidaskClub lowered Accuray from a “buy” rating to a “hold” rating in a research report on Thursday, February 8th. Zacks Investment Research lowered Accuray from a “buy” rating to a “hold” rating in a research report on Tuesday, March 27th. Finally, JPMorgan Chase lowered Accuray from a “neutral” rating to an “underweight” rating and set a $6.00 target price on the stock. in a research report on Wednesday, December 13th. Two analysts have rated the stock with a sell rating, three have issued a hold rating and three have given a buy rating to the stock. The stock currently has an average rating of “Hold” and a consensus target price of $7.21.
In other Accuray news, CEO Joshua Levine sold 8,675 shares of the business’s stock in a transaction dated Tuesday, April 3rd. The stock was sold at an average price of $4.65, for a total transaction of $40,338.75. Following the sale, the chief executive officer now owns 1,426,753 shares in the company, valued at approximately $6,634,401.45. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. In the last quarter, insiders have sold 14,257 shares of company stock worth $66,295. Company insiders own 3.90% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: “Accuray (ARAY) Receiving Somewhat Positive Media Coverage, Report Shows” was posted by BBNS and is owned by of BBNS. If you are viewing this report on another website, it was illegally copied and republished in violation of US and international copyright & trademark laws. The original version of this report can be accessed at https://baseballnewssource.com/2018/04/05/accuray-aray-earns-daily-media-sentiment-rating-of-0-10/2027510.html.
Accuray Incorporated designs, develops, and sells radiosurgery and radiation therapy systems for the treatment of tumors in the body. The company offers the CyberKnife System, a robotic stereotactic radiosurgery and stereotactic body radiation therapy system used for the treatment of various types of cancer and tumors in the body.
Receive News & Ratings for Accuray Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Accuray and related companies with MarketBeat.com's FREE daily email newsletter.